Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01147588 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating Effect of Esomeprazole, Omeprazole or Lansoprazole on the Pharmacodynamics (PD) and Pharmacokinetics (PK) of Clopidogrel
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 149
- Enrollment target
NCT01147588 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 149 participants.
The verdict
NCT01147588, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 149 participants
- Enrollment target
Study Summary
The aim of this study is to determine if there is a pharmacological interaction between clopidogrel and different types of proton pump inhibitors (PPIs), and if the extent of this possible interaction would change over time.
Interventions
- DRUG esomeprazole
- DRUG clopidogrel
- DRUG lansoprazole
- DRUG omeprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2010-05 |
| Est. Completion | 2011-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01147588
The ClinicalTrials.gov registry entry for NCT01147588 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 149 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which esomeprazole is the first listed.
NCT01147588 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01147588 about?
NCT01147588 is a clinical study titled "Study Evaluating Effect of Esomeprazole, Omeprazole or Lansoprazole on the Pharmacodynamics (PD) and Pharmacokinetics (PK) of Clopidogrel". The aim of this study is to determine if there is a pharmacological interaction between clopidogrel and different types of proton pump inhibitors (PPIs), and if the extent of this possible interaction would change over time.
What is the current status of trial NCT01147588?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 149 participants. The study started on 2010-05. Estimated completion is 2011-05.
What interventions are being tested in trial NCT01147588?
The interventions under investigation include: esomeprazole (DRUG), clopidogrel (DRUG), lansoprazole (DRUG), omeprazole (DRUG).
Who is sponsoring clinical trial NCT01147588?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.